Improved Time in Range and Postprandial Hyperglycemia with Canagliflozin in Combination with Teneligliptin : Secondary Analyses of the CALMER study

Cho, Kyu Yong; Nomoto, Hiroshi; Nakamura, Akinobu et al.

Journal of Diabetes Investigation, 2021, 12(8), 1417-1424

Permalink : https://hdl.handle.net/2115/82878

このアイテムのアクセス数:582件（2026-10-24 00:41 集計）

閲覧可能ファイル 

ファイル フォーマット サイズ 閲覧回数 説明
JDI 12 1417-1424 pdf 640 KB 360

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権
open access
URI
https://hdl.handle.net/2115/82878
タイトル
Improved Time in Range and Postprandial Hyperglycemia with Canagliflozin in Combination with Teneligliptin : Secondary Analyses of the CALMER study
著者
Cho, Kyu Yong ; Nomoto, Hiroshi ; Nakamura, Akinobu ; Kawata, Shinichiro ; Sugawara, Hajime ; Takeuchi, Jun ; Nagai, So ; Omori, Kazuno ; Tsuchida, Kazuhisa ; Miya, Aika ; Shigesawa, Ikumi ; Tsuchida, Kenichi ; Yanagiya, Shingo ; Kameda, Hiraku ; Yokoyama, Hiroki ; Taneda, Shinji ; Kurihara, Yoshio ; Aoki, Shin ; Nishimoto, Naoki ; Atsumi, Tatsuya ; Miyoshi, Hideaki
著者名
Cho, Kyu Yong
e-Rad_Researcher
50862330
著者名
Nomoto, Hiroshi
e-Rad_Researcher
70552420
著者名
Nakamura, Akinobu
著者名
Kawata, Shinichiro
著者名
Sugawara, Hajime
著者名
Takeuchi, Jun
e-Rad_Researcher
70507590
著者名
Nagai, So
著者名
Omori, Kazuno
著者名
Tsuchida, Kazuhisa
著者名
Miya, Aika
著者名
Shigesawa, Ikumi
著者名
Tsuchida, Kenichi
著者名
Yanagiya, Shingo
e-Rad_Researcher
20826127
著者名
Kameda, Hiraku
著者名
Yokoyama, Hiroki
著者名
Taneda, Shinji
著者名
Kurihara, Yoshio
著者名
Aoki, Shin
e-Rad_Researcher
90599630
著者名
Nishimoto, Naoki
e-Rad_Researcher
20301905
著者名
Atsumi, Tatsuya
e-Rad_Researcher
30360902
著者名
Miyoshi, Hideaki
言語
英語
キーワード
SGLT2 inhibitor
DPP-4 inhibitor
Post-Prandial Blood Glucose
Time in Range
発行日
2021-08-10
出版者
John Wiley & Sons
収録物名
Journal of Diabetes Investigation
巻(号)
12(8)
ページ
1417-1424
抄録
Aims/Introduction We recently reported the beneficial effect of the combination of SGLT2 inhibitor and DPP‐4 inhibitor on daily glycemic variability in patients with type 2 diabetes mellitus (T2DM). Additional favorable effects of combination therapy were explored in this secondary analysis. Materials and Methods The CALMER study was a multicenter, open‐label, prospective, randomized, parallel‐group comparison trial for T2DM involving continuous glucose monitoring (CGM) under meal tolerance tests (MTTs). Patients were randomly assigned to switch from teneligliptin to canagliflozin (SWITCH group) or to add canagliflozin to teneligliptin (COMB group). The CGM metrics, including time in target range (TIR), were investigated. Results All 99 participants (mean age: 62.3 years; mean HbA1c: 7.4%) completed the trial. TIR was increased in the COMB group (71.2% to 82.7%, p<0.001). The extent of the reduction in time above target range (TAR) was significantly larger in the COMB group compared with the SWITCH group (?14.8% vs. ?7.5%, p<0.01). Area under the curve values for glucose at 120 min after all MTTs were significantly decreased in the COMB group compared with the SWITCH group (p<0.05). Conclusions SGLT2 inhibitor combined with DPP‐4 inhibitor improved the quality of glycemic variability and reduced postprandial hyperglycemia compared with each monotherapy.
資源タイプ
学術雑誌論文
出版タイプ
Version of Record
権利情報
Creative Commons Attribution 4.0 International
PISSN
2040-1116
EISSN
2040-1124
関連情報 (isIdenticalTo)
出版社版DOI
https://doi.org/10.1111/jdi.13498